|
Friday June 25 |
| 09:00-09:45 |
Registration |
| |
|
| 09:45-10:00 |
Welcome |
|
|
|
Oral session I |
Software |
chair: A. Thomson |
| 10:00-10:15 |
C. Pobel |
NONMEM running on a PC workstation: installation and use in a Clinical Pharmacy Department |
| 10:15-10:30 |
P. Girard, A. Laffont, J.P. Boissel |
Interface between NONMEM output and an Exploratory Data Analysis Tool |
| 10:30-10:45 |
D. Stephens |
The POPKAN Software |
| 10:45-11:00 |
R. Gomeni |
P-Pharm : A Population Pharmacokinetic-Pharmacodynamic Data Modeling Program |
| 11:00-11:30 |
Coffee break |
|
|
|
Oral session II |
Comparison of methodologies |
chair: W. Weber |
| 11:30-12:00 |
J. Wakefield |
Comparison of approaches - Population Pharmacokinetics of Quinidine |
| 12:00-12:15 |
N. Best, W. Gilks, K. Tan |
Population Pharmacokinetic Modelling using the GIBBS Sampler |
| 12:15-12:30 |
M.C. Iliadis, R. Bruno, V. Cosson, J.C. Vergniol, A. Mallet, G. Montay, D. Oulid-Aissa, M. Marty, M. Clavel, M. Aapro, A. Frydman, M. Bayssas, A. Iliadis |
Taxotere Population Pharmacokinetics during Phase I Studies : Comparison of NONMEM and NPML |
| 12:30-12:45 |
E. Fuseau, S. Lettis, L. Lacey |
Simulated Population Pharmacokinetic Data for Use in Assessing the Robustness of Current Population Methods |
| 12:45-14:00 |
Lunch |
| |
|
|
Oral session III |
|
chair: J. Van Bree |
| 14:00-14:15 |
L. Aarons |
The use of an EM algorithm for parameter estimation from spare data |
| 14:15-14:30 |
F.Y. Bois, D. Maszle, A. Gelman |
A Toxicokinetic Analysis of Tetra Chloroethylene Methabolism in Humans |
| 14:30-14:45 |
L.S. Murray, S. Senan, J. Cassidy, P. Workman, S.B. Kaye, M.A. Graham |
A Preliminary report on the Pharmacokinetics of Tirapazamine |
| 14:45-15:00 |
C. Laveille, M. Chic, F. Dubois, R. Jochemsen |
Indapamide population pharmacokinetics via mixed effects modeling: models building and bayesian estimation of pharmacokinetics parameters |
| 15:00-15:15 |
W. Weber, L. Harnisch |
Population pharmacokinetics in paediatric patients : comparison of empirical renal clearance models |
| 15:15-15:30 |
A. Laffont, P. Girard, P. Maire, X. Barbaut, G. Chapelle, C. Pobel, T. Berod, C. Pivot, B. Lacarelle, J. Debord, R.W. Jelliffe, J.P. Boissel |
Multicenter study of Amikacyn Pharmacokinetics from patients under TDM |
| 15:30-15:45 |
N. Taright, F. Mentré, R. Jouvent, S. Ammar, A Mallet |
Population analysis of the kinetics of litium using NPML and evaluation of the estimated characteristics on a group of patients regimen |
| 15:45-16:30 |
Tea break |
| |
|
|
Tutorial |
|
chair: S. Vozeh |
| 16:30-17:30 |
F. Mentré |
Optimal Design in Population Analysis Including Bayesian Aspects |
|
|
Oral session IV |
Population approach in Drug Development |
chair: S. Vozeh |
| 17:30-17:45 |
J.L. Steimer |
Points to consider when presenting population analysis to regulatory autorities |
| 17:45-18:00 |
A. Van Peer |
International Harmonisation of Guidelines on Studies in Special Patient Populations |
| 18:80-18:15 |
R. Bruno, T. Joumard, N. Vivier, J.C. Vergniol, V. Cosson, G. Montay, F. This, M. Bayssas, A. Frydman |
Implementation of Population Pharmacokinetic Studies during Drug Development : Success Factors |
| |
|
|
|
| 18:15-18:30 |
PAGE prospects : general discussion (R. Bruno, P. Girard, J.L. Steimer, B. Tranchand)
COST B1 - Next meeting(s) ? - Organizing Committee |
|
|
| 18:30 |
End of the meeting |
